Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Bifunctional MAPK/PI3K Antagonist for Inhibition of Tumor Growth and Metastasis.

Molecular cancer therapeutics - 1 Nov 2017

Galbán Stefanie, Apfelbaum April A, Espinoza Carlos, Heist Kevin, Haley Henry, Bedi Karan, Ljungman Mats, Galbán Craig J, Luker Gary D, Dort Marcian Van, Ross Brian D

Abstract excerpt

Responses to targeted therapies frequently are brief, with patients relapsing with drug-resistant tumors. For oncogenic MEK and BRAF inhibition, drug resistance commonly occurs through activation of PI3K/AKT/mTOR signaling and immune checkpoint modulation, providing a robust molecular target for concomitant therapy. Here, we evaluated the efficacy of a bifunctional kinase inhibitor (ST-162) that concurrently...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Apoptosis
Share to Colorectal Neoplasms

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Enzyme Inhibitors

Share to Gene Expression Regulation, Neoplastic

Share to Liver Neoplasms

Share to Melanoma

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 28775144
DOI: 10.1158/1535-7163.MCT-17-0207
PMCID: PMC5669819

Genes

BRAF
KRAS
PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Bifunctional MAPK/PI3K Antagonist for Inhibition of Tumor Growth and Metastasis.PMID 28775144Read ↗

Rational Approaches for Combination Therapy Strategies Targeting the MAP Kinase Pathway in Solid TumorsSemantic proximity Read ↗

Design and biological characterization of a series of dual mechanism ERK1/2 inhibitors with a Triazolopyridinone core.Semantic proximity Read ↗

The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer.Semantic proximity Read ↗

Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib).Semantic proximity Read ↗

From poor prognosis to precision promise: Clinical trials targeting BRAF-mutant metastatic colorectal cancer.Semantic proximity Read ↗

Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.Semantic proximity Read ↗

AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS -Mutant Tumor Models when Combined with the MEK Inhibitor, SelumetinibSemantic proximity Read ↗

Targeted therapy for melanoma: rational combinatorial approaches.Semantic proximity Read ↗

Rationally designed treatment for metastatic colorectal cancer: current drug development strategies.Semantic proximity Read ↗

Targeting BRAF-Mutant Colorectal Cancer: Progress in Combination Strategies.Semantic proximity Read ↗

Activated MKK3/MYC crosstalk impairs dabrafenib response in BRAFV600E colorectal cancer leading to resistance.Semantic proximity Read ↗

ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERKSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.